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Abstract
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miRNAs are noncoding RNA molecules that regulate gene expression through diverse
mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or
repressing miRNA expression and activity, hold great promise. However, the efficient delivery of
miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic.
Cationic polymers or viral vectors are efficient delivery agents but their systemic toxicity and
immunogenicity limit their clinical usage. Efficient targeting and sustained release of miRNAs/
anti-miRNAs using nanoparticles (NPs) conjugated with antibodies and/or peptides could reduce
the required therapeutic dosage while minimizing systemic and cellular toxicity. Given their
importance in clinical oncology, here we focus on the development of miRNA nanoformulations to
achieve enhanced cellular uptake, bioavailability, and accumulation at the tumor site.

Keywords
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Introduction
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miRNAs are 22 nucleotide-long, noncoding RNA molecules that act as negative regulators
of gene expression and regulate a range of biological functions, including cell survival,
proliferation, apoptosis, tumor growth, and metastasis [1]. miRNAs bind to a complimentary
mRNA sequence and result in post-translation repression or degradation and silencing.
miRNAs are formed by transcription of RNA polymerase II, which folds back to form a
distinctive hairpin structure, whereas other small mRNAs are formed from longer hairpin
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structures [2]. Processing of miRNAs as primary (pri)-miRNA and pre-miRNA (in the
nucleus); mature miRNA duplexes, RNA-induced silencing complex (RISC) strandmediated complex, and complementary mRNA sequence formation cause translation
repression and mRNA degradation (in the cytoplasm) [3,4].
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miRNAs have significant roles in cancer, as evident from the more than 25 000 peerreviewed reports (Figure 1A) and clinical studies on this topic over the years. Although
several miRNAs modulating carcinogenic processes have been identified, their clinical
translation is limited because of their unsuccessful delivery at the tumor site and their broad
functionality, which results in off-target effects. Lentiviral vectors have shown efficient
cellular delivery, but their activation of oncogenes and/or excessive immunogenicity raise
concerns over the safety of genomic integration. To overcome such limitations, nonviral
miRNA delivery systems, such as polyethyleneimine (PEI)-based NPs, liposomes, polymeric
micelles, dendrimers, magnetic NPs, and polymeric NPs (Figure 1B), have been proposed.
These delivery systems protect the degradation of miRNAs by nucleases and increase their
half-life in the blood [5], can escape from endosomal and/or lysosomal degradation, and
deliver miRNAs to the cytoplasm or nucleus (Figure 1C). The first miRNA replacement
therapy to enter clinical trials involved the restitution of a tumor suppressor miRNA
(miR-34) in modified liposomes (MRX34, Mirna Therapeutics;
www.mirnatherapeutics.com/pipeline/mirna-MRX34.html). MRX34 showed promising
results in a Phase I clinical trial, where partial responses where observed in patients with
renal cell carcinoma (RCC), acral melanoma, or hepatocellular carcinoma. Many patients
with advanced-stage disease showed promising results while on treatment. Thus, the
company plans to start two Phase 2 trials with MRX34 for patients with RCC and melanoma
by the end of 2016. Given the clinical impact of miRNAs in cancer, we review here the
strategies implemented for the delivery of tumor suppressor miRNAs or anti-miRNAs using
nanotechnology-based formulations for the treatment of various types of cancer.

Delivery of miRNAs: major obstacles and nanotechnology

Author Manuscript

Although accumulating scientific evidences proves that the role of miRNAs is significant in
cancer, translation into clinical applications has several issues. The main reasons include
poor systemic stability, rapid clearance, and lack of efficient delivery. In general,
oligonucleotides in the bloodstream have a half-life of a couple of minutes; however,
suitable substitution can improve the half-life to several hours [6]. The kidney is one of the
barriers that readily accumulates and clears oligonucleotides from the body via renal
clearance. The liver is another organ that abundantly takes up these oligonucleotides for
clearance from the body [6]. The other major barrier is the reticuloendothelial system (RES),
in which Kupffer cells of liver and spleen macrophages eliminate these oligonucleotides
from the circulation system. Phagocytosis of the oligonucleotide results in a phagosome,
which is then integrated into the lysosome, where it is degraded by nucleases [6]. Nuclease
activity in plasma and tissue degrade the oligonucleotide very rapidly. This phenomenon can
be avoided by targeted delivery of NPs to cancer cells [7]. Nanocarrier-mediated
oligonucleotide delivery is capable of crossing endothelial cells into the interstitial space of
the tumor [6]. In addition, oligonucleotides can be delivered into the cytoplasm for
translation via endocytosis using a nanocarrier that can escape endosomal degradation.
Drug Discov Today. Author manuscript; available in PMC 2018 February 01.

Ganju et al.

Page 3

Author Manuscript

There are many NPs or nanocarriers being used to deliver miRNAs, each uniquely
formulated and with distinctive composition.
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One of the most widely used groups of polymers for the delivery of nucleic acids to cells are
cationic polymers, because, being positively charged, these can be conjugated to the
negatively charged nucleic acids. They also present low toxicity and low immunogenic
responses compared with other polymer-based systems for gene delivery [8]. Cationic
polymers are subdivided into naturally derived and synthetically derived polymers. Naturally
derived cationic polymers include chitosan (CS), dextran, gelatin, cellulose, and cyclodextrin
polymer, whereas synthetically derived cationic polymers include PEI, poly(L-Lysine),
poly(amido amines), poly(amino-co-ester), poly-(2-N,N-dimethylaminoethylmethacrylate),
and dendrimers, of which PEI and its conjugates have been widely exploited for gene
delivery purposes [8]. Low-molecular-weight PEI polymers are considered to be efficient
carriers for the delivery of small nucleic acids, miRNAs, and small interfering (si)RNAs
because of their low toxicity compared with other transfection agents [9]. The main
advantage of the PEI-based delivery system is the rapid uptake and release (`proton sponge
effect') (Figure 1C) of the nucleic acid inside the cell via an endocytic mechanism [9].
Schade et al. [10] showed that the combination of PEI with a magnetic NP formulation led
to efficient delivery of the nucleic acid to target cells. Quantum dots (QDs) conjugated to
PEI can enhance theranostic applications to provide imaging, gene delivery, and cellular
labeling [11]. However, limitations associated with the PEI delivery system include poorer
biodegradability inside the cell, leading to its accumulation and cytotoxicity [12]. Therefore,
new research leading to improved PEI-based delivery systems is needed.
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Liposomes are amphiphilic molecules that comprise phospholipids, are biocompatible and
biodegradable, and, to a great extent, resemble the cell membrane of a human cell [13].
Given their resemblance to the cell membrane bilayer, liposomes have a tendency to pass
through cell membranes and release their encapsulated payloads (i.e., miRNAs). The issues
of low sensitivity or specificity and toxicity [13] can be overcome by surface modification,
as detailed in Table 1. Polymeric micelles, which are highly soluble in water, have been
largely identified as suitable carriers for, and distributors of, anticancer drug(s). These
micelles have an outer and inner core that determine the different physicochemical
properties of these nanocarriers [14]; for example, their surface composition,
hydrophobicity, and crystallinity [14] determine the payload release. NPs comprising
polymers, lipids, hybrids, and metal/metal oxides provide significant opportunities for
targeted delivery [15]. NPs readily accumulate at tumor sites because of an `enhanced
permeability and retention' effect [16].

Author Manuscript

Here, we discuss various novel strategies to circumvent antisense targeting and delivery to
cancer cells through the use of nanotechnology.

Using nanotechnology formulations to deliver miRNAs to tumors
Breast cancer
miRNA nanoformulations targeting hyaluronic acid (HA) receptors, which are
overexpressed in breast cancer, is a novel approach. A recent study showed that HA-CS NPs
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efficiently delivered tumor suppressor miR-34a and doxorubicin (Dox) to breast cancer cellderived xenograft tumors in athymic nude mice, resulting in the increased inhibition of
tumor growth and tumor volume compared with Dox-NPs or free Dox [17]. HA-CS-coated
PEI-poly(D,L-lactide-co-glycolide) (PEI-PLGA) NPs conjugated with dox and miR-542-3p
both improved targeting and increased the uptake of NPs in triple-negative breast cancer
cells [18]. Furthermore, delivery of PLGA-PEG NPs encapsulating antisense-miR-21 and
orlistat or orlistat NP in combination with Dox significantly enhanced apoptotic effects in
MDA-MB-231 and SKBR-3 triple-negative breast cancer cells [19]. In another study,
PLGA-b-PEG NPs were successful in delivering anti-sense miR-21 and miR-10b in triplenegative breast cancer [20]. A nanoporous silicon microparticle modified by arginine-PEI in
combination with miR-18a has been used to target breast cancer cells and resulted in a 90%
knockdown of ATMK (an miR-18a target gene) and a significant reduction in tumor volume
in a murine model of MDA-MB-231 cells [21]. Another CS-based nanoformulation
incorporating negatively charged poly(γ-glutamic acid) (PGA) was conjugated with QDmiRNA let-7a-gold NP (QD-RNA-Au NP) for delivery to breast cancer cells where Dicermediated release of QD resulted in fluorescence, demonstrating its theranostic effectiveness
[22]. Anti-miR-21 delivery with a PEI/poly(sodium 4-styrenesulfonates) (PSS)/grapheme
oxide (GO) nanocomplex conjugated to adriamycin inhibited 40% of miR-21 and 45% of
ABC transporter expression levels and resulted in a twofold increase in uptake of adriamycin
[23]. In a recent study, intravenous injection of exosomes conjugated with epidermal growth
factor (EGF) peptide targeting EGF receptor (EGFR)-expressing cells with encapsulated
let-7a was shown to be effective in xenograft mouse models of breast cancer cells [24].
Prostate cancer
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Various miRNAs, including miR-34a, −21, and −153, have been implicated in prostate
tumorigenesis [25]. A recent study demonstrated that the delivery of CS-encapsulated
miR-34a intrafemorally reduced bone tumor growth and volume by twofold [26]. Exosomes
have been shown to effectively deliver anti-miR-21 oligonucleotides to prostate cancer cells,
leading to a significant downregulation of miR-21 levels and decreased motility of prostate
cancer cells [27]. miR-34a delivery has shown chemosensitization of paclitaxel treatment in
prostate cancer cells by targeting the Bcl-2 protein [28]. Let-7c miRNA, conjugated with a
NP-based system targeted for prostate cancer cells using anti- prostate specific membrane
antigen (PSMA) antibody or aptamer conjugation, showed enhanced targeting and uptake.
Gold NPs formulated for the delivery of miRNAs into cancer cells showed a payload that
was approximately 10–20 times higher than that of lipofectamine, lower toxicity, efficient
uptake, fast endosomal[DE1], and increased half-live [29]. Introduction of disulfide linkage
in PEI (SSPEI) led to better biocompatibility and reduced the associated toxicity, whereas
delivery of polyarginine peptide (R11)-labeled SSPEI NP showed specific uptake in prostate
cancer cells [30]. This strategy not only reduced toxicity, but also enhanced the restitution of
the tumor suppressor miR-145 to prostate cancer, resulting in decreased tumor burden in
xenografted mice.
Pancreatic cancer
Deregulation of miRNAs has been shown in pancreatic cancer, leading to enhanced tumor
growth and metastasis [31]. Various miRNAs, such as miR-221, −21, −375, −34a, and −145,
Drug Discov Today. Author manuscript; available in PMC 2018 February 01.
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have been implicated in pancreatic carcinogenesis. miR-221 has been known to function as
an oncogene by promoting the growth of pancreatic ductal adenocarcinoma (PDAC) by
regulating the key oncogenic PTEN-AKT pathway [32] and increased expression of matrix
metalloproteases (MMP), such as MMP-2 and MMP-9 [33]. miR-145 functions as a tumor
suppressor in pancreatic cancer and is known to target Mucin 13 (MUC13) to inhibit
pancreatic cancer growth and invasion [34]. A magnetic NP formulation encapsulating
miR-145 efficiently delivered miR-145 to the tumor site and downregulated the expression
of oncogenic signaling, such as MUC13, HER2, and pAKT, to inhibit pancreatic cancer
growth and invasion [35]. NP-encapsulated delivery of miRNA for pancreatic cancer
treatment remains an unexplored field that has potential therapeutic value. In a previous
report, tumor suppressor miR-34a restitution was achieved using an antibody-modified
liposome/polycation delivery system in a Panc-1 xenograft mouse model [21]. Gold NPs
with fluorophore-labeled hairpin DNA, so-called `gold nanobeacons', were used to target
and silence miR-21, an endogenous miRNA involved in cancer development and
chemoresistance [36]. The miR-375 expression level in pancreatic cancer is associated with
the carcinogenesis of pancreatic cancer cells. A solid lipid NP delivery system in
conjugation with miR-375 efficiently reached pancreatic tumors and inhibited pancreatic
cancer growth in vitro and in in vivo models. The delivery of miR-150-encapsulated NPs
increased the expression of miR-150 in Colo-357 and HPAF cells by 28- and 26-fold,
respectively, compared with transfection of miRNA via lipofectamine [37].

Author Manuscript

Ovarian cancer
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The efficient delivery of anti-miR-21 to ovarian cancer cells has been observed to reduce the
tumor initiation cell burden [38]. A recent study showed a gold NP delivery system for antimiR-21 to be an excellent platform to target and silence miR-21 in ovarian cancer cells,
inhibiting the sphere-forming capacity of tumor-initiating cells. miR-155 is downregulated
in ovarian tumor-associated dendritic cells (DCs) and is essential for optimal antigen
presentation and activation of T cells by DCs [39]. PEI-based nanocomplexes were used to
deliver miR-155 to tumor-associated DC, which increased the expression of miR-155 in
vitro and resulted in increased antitumor immunity and, thus, increased survival of the mice
(by 65%) [39]. miR-124 is downregulated in ovarian cancer and acts as a tumor suppressor
by targeting proteins such as myc and Rb and increasing the expression of p27, subsequently
leading to cell cycle arrest at G1 phase because of the loss of phospho-Rb and decreased
expression of the myc protein [40]. Transfection of miR-124 in an ovarian cancer cell line
reduced the invasive and migratory capability of ovarian cancer cells and increased their
sensitivity to etoposide by twofold. Another miR-124 miRNA, which acts as a tumor
suppressor in ovarian cancer, modulating cell cycle-regulating genes, was efficiently restored
in ovarian cancer cell xenograft tumors using 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) NPs. These DOPC NPs significantly restored miR-124 in tumors, resulting in a
significant decrease in tumor weight alone or in combination with etoposide [40].

Author Manuscript

Lung cancer
Recent studies demonstrated the feasibility of systemically delivering miRNA mimics and
siRNAs simultaneously to lung adenocarcinoma cells using polymer-based NPs in a mouse
model of lung cancer, eliciting a potent antitumor response. [41]. It was shown that miR-34a
Drug Discov Today. Author manuscript; available in PMC 2018 February 01.
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acts as a tumor suppressor and is significantly downregulated in lung cancer [42]. miR-34a
targets the p53 signaling pathway to regulate cell cycle progression and apoptosis induction
in cancer cells [42]. Liposomes encapsulating miR-34a were effectively delivered to lung
cancer cells to mediate the inhibition of cell cycle progression and activation of apoptosis in
lung cancer cells, thereby causing a significant decrease in tumor cell growth and volume in
an orthotopic mouse model of lung cancer [43]. miR-200c is a known negative regulator of
ZEB1, which induces the epithelial–mesenchymal transition (EMT) in cancer cells [44].
Liposomal NP-encapsulated miR-200c delivered to lung cancer cells induced the activation
of oxidative stress response genes and enhanced the radiosensitivity of lung cancer cells up
to 1.5 times in an in vivo mice model [45]. Multifunctional aptamer conjugated to miRNA is
another method of delivering tumor suppressor genes, such as let7g, to lung cancer cells,
significantly reducing tumor volume compared with aptamer treatment alone [46]. miR-29b
is downregulated in non-small cell lung cancer (NSCLC) cells and directly targets oncogene
cyclin-dependent kinase 6 (CDK6) to regulate cell cycle progression in these cells [47,48].
Cationic lipoplex-based delivery of miR-29b to lung cancer cells effectively reduced CDK6
expression by almost 54% and reduced tumor volume by almost 50% in vivo [48].
Brain cancer

Author Manuscript

Poly(amido amine) (PAMAM) has been found to be an effective carrier for the delivery of
miR-7 into glioma cells owing to its low toxicity, high solubilization, and delayed release
[49]. A recent study demonstrated the successful delivery of tumor suppressor miRNA
(let-7a)-conjugated magnetic NPs to brain cells followed by magnetic hyperthermia. In
another study, PLGA NPs encapsulating antisense miR-21 were found to be effective in the
delivery and sustained silencing of miR-21 function in glioblastoma cells [50]. Mesoporous
silica NPs containing polyarginine-peptide nucleic acid (R8-PNA) conjugates targeting
miR221 were used to treat temozolomide (TMZ)-resistant glioma cells. These NPs,
combined with TMZ treatment, led to a significant increase in apoptosis [51].

miRNA-mediated sensitization therapeutics
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Recently, the combination treatment of miRNA therapeutics with small-molecule anticancer
drugs has received much attention because of its superior therapeutic benefit (Figure 2). This
approach has many advantages over conventional therapies, such as reverting the EMT,
inhibiting drug resistance build-up, promoting apoptosis and autophagy, suppressing tumor
angiogenesis, and inhibiting the expression of efflux transporters, such as P-glycoprotein
[52]. By actively targeting oncogenic miRNAs using an anti-miR system or restoring lost
tumor suppressor miRNAs, it is possible to sensitize cells to chemotherapeutic drugs. This
treatment modality resulted in smaller tumor nodules in vivo, which are less likely to show
tumor relapse. Co-delivery of miRNA/siRNA along with chemotherapeutic drugs is
recommended because it has additive or synergistic effects. Chemotherapeutic drugs can
inhibit cancer growth and proliferation but, over a period of time, cells acquire resistance
against these drugs because of the increased expression of efflux transporters and
antiapoptotic signaling. The miRNA/siRNA platform helps to overcome drug resistance by
directly targeting efflux transporter expression and antiapoptotic signaling, thereby
sensitizing cancer cells to chemotherapeutic drugs [53]. This co-delivery system is an
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exciting platform that holds promise as a better therapeutic modality for treating cancer cells
and, thus, requires further investigation. Another study using a dual miRNA combination of
miR-21 and miR-10b in triple-negative breast cancer showed promising outcomes for
miRNA combination therapies with drugs or with other miRNAs [20]. A recent study
demonstrated that lipid NP-loaded miR-34a with paclitaxel induced increased anticancer
effects compared with paclitaxel or miRNA alone [54]. miR-205 is known to sensitize
pancreatic cancer cells to gemcitabine by targeting chemoresistance markers (i.e., OCT3/4,
CD44, and Tubulin β3) [55]. Gemcitabine-miR-205 conjugated micelles showed a highly
significant reduction in tumor volume compared with gemcitabine alone in an in vivo
pancreatic cancer model, thereby suggesting a synergistic or additive effect of the
combination treatment on tumor cells [56]. miR-34a directly targets Notch-1 signaling in
breast cancer, thereby inhibiting cell proliferation, invasion, and chemoresistance [57]. Dox
conjugated to miR-34a HA-CS NPs not only targeted breast cancer cell migration by
inhibiting Notch-1 signaling, but also sensitized cells to Dox by suppressing Dox-mediated
activation of Bcl-2 expression at both the protein and transcriptome levels [57]. miR-21 is
known to modulate sensitivity to chemotherapeutic drugs [58]. Co-delivery of an antimiRNA system with chemotherapeutic drug also holds promise as an improved treatment
modality. miR-21 has been proven to be an oncogenic miRNA in various types of cancer,
and suppresses PTEN expression, thus promoting Akt-mediated activation of Bcl-2 signaling
and inducing chemoresistance in cancer cells [59]. Co-delivery of miR-21 inhibitor
conjugated to Dox encapsulated in a star-branched copolymer comprising poly(lactic acid)
and poly(dimethylaminoethyl methacrylate) showed excellent anticancer efficacy. Tumor
volume in glioma cells decreased by ninefold compared with control, suggesting a
promising treatment approach combining gene delivery and chemotherapeutic drugs [60].
miR-200c targets class III beta-tubulin and CD44, improves the sensitivity of cancer cells to
chemotherapeutic drugs, and reverts EMT by increasing E-cadherin expression [61,62].
Gelatinase-stimuli NPs for co-delivery of miR-200c and Dox in cancer stem cells (CSC)
resulted in a 75% decrease in tumor volume compared with control, again suggesting a
synergistic effect of combination treatment [63]. Development of multidrug resistance in
breast cancer cells occurs when the miR-21-mediated signaling pathway enhances
expression of efflux transporters, such as P-glycoprotein, which are then overexpressed in
cancer cells [64,65]. Graphene NPs have excellent physical and mechanical properties. It
was shown that adriamycin and miR-21 inhibitor encapsulation in graphene NPs had more
pronounced antiproliferative effects on adriamycin-resistant MCF7 breast cancer cells [23].
Similarly, co-delivery of miR-21 inhibitor with 5-fluorouracil (5-FU) using a poly(amido
amine) dendrimer showed an enhanced cytotoxic effect compared with 5-FU alone in
glioblastoma cells [66]. Delivery of anti-miR-21 with poly(L-lysine)-modified PEI NPs
breast cancer cells increased cell cycle arrest in G1 phase, enhanced PDCD4 expression (a
direct target of miR-21), and led to apoptosis by increased expression of caspase-3.
Furthermore, it decreased the IC50 of Dox from 0.585 to 0.415 Mg/ml and that of cisplatin
from 1.051 to 0.940 Mg/ml, showing the synergistic effect of this anti-miR21 and
chemotherapeutic drug treatment [67].
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Targeted drug delivery system
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A possible solution to the problem of cell-specific delivery of therapeutic miRNAs/antimiRNAs is the utilization of targeted miRNA mimics. The problem with NP-mediated
miRNA and/or drugs is that uptake by cancer cells is not specific; however, this can be
circumvented utilizing targeted approaches by coating the surface of NPs with specific
antibodies or ligands against proteins that are specifically expressed in cancer cells. The
targeted delivery of curcumin (a natural product) was shown in C4-2 prostate cancer cellderived xenograft tumors using PLGA NPs conjugated with I-131-labeled PSMA antibody
[68,69]. These results showed significantly reduced prostate tumor burden, and the efficient
delivery of curcumin to targeted prostate tumors with reduced or no uptake by other organs.
This novel targeted PSMA delivery system can be used to co-deliver miRNAs and
chemotherapeutic drugs to prostate cancer cells in a specific manner without any adverse
effects. PSMA ligand-conjugated polymeric micelles have also been used to target prostate
cancer cells. Transferrin-coated NPs have shown an excellent ability to pass through the
blood–brain barrier and showed increased cytotoxic effects with zoledronic acid compared
with free zoledronic acid in glioblastoma cells [70]. Folate receptors are highly expressed in
breast cancer cells and NPs conjugated to the folate receptor for delivery of siRNA led to the
specific uptake of NPs by breast cancer cells and the efficient delivery of siRNA to the
cancer cells [71]. Aptamer-mediated delivery of short RNA therapeutics in cancer cells [72]
has been studied, with promising results, and this system can be further enhanced by
aptamer-conjugated drug NPs encapsulating short RNA therapeutics and chemotherapeutic
drugs for enhanced cytotoxic activity.
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These examples show that the targeted delivery of short RNA therapeutics combined with
chemotherapeutic drugs not only increases uptake by cancer cells specifically, but also
inhibits chemoresistance in cancer cells and enhances their cytotoxic effects, suggesting a
synergistic effect of combinational therapy. Interleukin (IL)-10 is an important
immunoregulatory cytokine and has an important role in T regulatory cell function [73].
Let-7b directly suppresses IL-10 expression in T cells and expression of let-7b regulates
tumor-associated macrophages (TAMs) and tumor infiltrating DCs (TIDCs), leading to
increased immune responses against the cancer cells [74]. Conjugation of let-7b miRNA to
mannose moieties (TAMs and TIDCs express high levels of mannose receptors) and pHresponsive PEG-histamine-modified alginate, which disintegrates in acidic
microenvironments, led to the targeted delivery of let-7b. This nanocomplex formulation
showed improved survivability in tumor-bearing mice, with nearly 50% of let-7b-treated
mice still alive 50 days after the start of treatment. In addition, this formulation resulted in
decreased tumor weight and volume along with decreased levels of M2 macrophage
markers, with a subsequent increase in M1-specific gene (iNOS) and decreased expression
of TIDCs markers, such as CD40 and CD80 [74]. A miRNA nanobeacon constructed with
HA and miR-34a efficiently targeted cancer cells and endocytosis through the CD44
receptor, which was observed both in vitro and in vivo [75] (Figure 3). Such specific
targeting would improve therapeutic outcomes. A future goal would be to construct a unique
nanoplatform that has inbuilt therapeutic components in addition to miRNAs, and a specific
targeted moiety to specifically to kill or eradicate cancer cells.

Drug Discov Today. Author manuscript; available in PMC 2018 February 01.
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Concluding remarks
The successful delivery of miRNAs to cancer cells is a major hurdle in cancer therapeutics.
In this review, we have focused on various advanced nanoformulations and new
methodologies for the successful delivery of miRNAs to tumor cells. Via these
complexation, encapsulation, and conjugation nanotechnology strategies, miRNAs can be
delivered that target the tumor in passive, active, and stimuli-responsive ways. Furthermore,
because of the high fibrosis and heterogeneity of tumor tissues, a single theranostic
nanoformulation with simultaneous therapeutic and imaging capabilities is of current
interest. In addition, nanosystems have shown reduced systemic toxicity, which has been an
important concern with earlier conventional transfection systems.
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Highlights
•

MicroRNAs play a major role in cancer

•

Several clinical trials with microRNA are reported for cancer treatment

•

Delivery of microRNA encounters several challenges

•

We report successful microRNA nano-mediated delivery for the treatment of
cancer
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[DE11]Scientific evidence and nano-based delivery of miRNAs for cancer therapeutics. (A)
Publications reporting miRNA (green bars) and miRNA delivery (red bars in insert) using
nanoparticle (NP) formulations from 2005 to July 2016. Data was collected from PubMed
on July 26, 2016. (B) Structural differences in nanoparticle formulations used for miRNA
delivery. (i) Polyethyleneimine (PEI) or cationic polymer-based nanoassemblies; (ii)
liposomal formulations; (iii) polymer micelles; (iv) polymer NPs; (v) metal or magnetic
NPs; and (vi) dendrimer-based formulations. (C) Possible routes of miRNA uptake
mechanisms in cells: clathrin, caveolin, and receptor-mediated endocytosis. The proton
sponge effect leads to the release of miRNAs from NPs.
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[DE12]miRNA-mediated chemosensitization of cancer cells for improved therapeutics.
Schematic representation: Step 1: loading of nanoparticles (NPs) with miRNA and drug
molecules. Step 2: antibody conjugation reaction for targeted delivery; Step 3: targeted
binding and intracellular release of miRNA induces chemosensitization; and Step 4: drug
release promotes apoptosis in cancer cells.
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Hyaluronic acid (HA) conjugation offers superior targeted delivery of miRNAs in breast
cancer cells. (A) Schematic representation of a miR-34a-targeted nanoformulation
preparation and in vitro specific targeting of triple-negative breast cancer cells. (B) In vivo
whole-mice imaging of miR-34a nanoparticles (NPs) in an orthotopic breast cancer mouse
model at different time points after intravenous injection. (C) Photon intensity of tumor
region after injection of NPs. (D) Ex vivo excised tumor tissue exhibiting superior targeting
potential of HA-conjugated NPs. Reproduced, with permission, from [72].
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Surface modification of NPs facilitates miRNA binding and successful drug delivery
Nanoformulation

Modification

miRNA

Refs

PEI/poly(L-lysine)

HA

miR-542-3p

[18]

E-selectin

miR-146a/miR-181b

[76]

Polyarginine

miR-145

[30]

Carboxymethyl-hexanoyl CS

miR-122

[77]

Rabies virus glycoprotein

miR-124a

[12]

Chlorotoxin

miR-21

[78]

Surfactant protein C

miR-486

[79]

Ephrin-A1

Let-7a

[80]

Cyclic RGD

miR-296

[81]

Transferrin

miR-1

[82]

Transferrin

miR-29b

[83]

N-lactobionyl-dioleoyl-phosphatidylethanolamine

miR-155

[84]

Gold NPs

Folic acid

miR-122

[85]

PEG-peptide-poly(ε-caprolactone) copolymer NPs

Gelatinase

miR-200c

[63]

Silica NPs

GD2

miR-34a

[86]

PLGA

Cyclic RGD

miR-132

[87]

uPA

miR-10b and miR21

[20]

PEI

miR-145/9/21

[88]

Cy3-DNA probe

Let-7

[89]

Lanthanide cations

miR-99a/486/21

[90]

PEG

miR-16

[91]

Liposomes

Author Manuscript

Magnetic NPs

Author Manuscript
Author Manuscript
Drug Discov Today. Author manuscript; available in PMC 2018 February 01.

